Nicole Brossier

Profile picture
Resident, Residency
Hematology and Oncology

phone: (314) 454-6018


  • BS, University of Missouri-Rolla2004
  • MD, University of Alabama School of Medicine2013
  • PhD, University of Alabama-Birmingham2011


  • Pediatrics Residency, Washington University in St. Louis / St. Louis Children's Hospital2013 - 2016
  • Pediatric Hematology/Oncology Fellow, Washington University in St. Louis / St. Louis Children's Hospital2016 - 2019

Licensure and Board Certification

  • 2017 - PresMO, Medical License
  • 2017 - PresABP Board Certified (General Pediatrics)
  • 2021 - PresPediatric Hematology-Oncology

Honors and Awards

  • ASIP Trainee Travel Award to Experimental Biology 20082008
  • HCS Travel Award to Experimental Biology 20082008
  • ASIP Abraham D. Sobel Educational Fund Scholar Award 20092009
  • HCS Histochemist-in-Training Award 20092009
  • Alex's Lemonade Stand Young Investigator Award2019
  • CTF First Time Conference Travel Award2019
  • Hyundai Hope on Wheels Young Investigator Award2020
  • K12 Child Health Research Center Development Award2020
  • Francis Collins Scholar Award2021

Recent Publications view all (11)

Publication Co-Authors

  1. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in Neurofibromin-Null MPNST Cells. ++These two authors contributed equally to this work. Cell Communication and Signaling. 2021. 
  2. Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma. Neuro Oncol. 2021;23(4):625-637. doi:10.1093/neuonc/noaa237  PMCID:PMC8041339  PMID:33080011 
  3. Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape. Lancet Child Adolesc Health. 2020;4(7):488-490. PMID:32562630 
  4. Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells. J Neuropathol Exp Neurol. 2015;74(6):568-86. PMCID:PMC4433624  PMID:25946318 
  5. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 2015;15(4):415-23. PMID:25652347 
  6. Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis. Acta Neuropathol. 2014;127(4):573-91. PMCID:PMC3999224  PMID:24232507 
  7. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res. 2013;73(14):4395-405. PMCID:PMC3715566  PMID:23722551 
  8. Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands. J Neuropathol Exp Neurol. 2013;72(3):219-33. PMCID:PMC3579504  PMID:23399900 
  9. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am J Pathol. 2013;182(3):646-67. PMCID:PMC3586689  PMID:23321323 
  10. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brain Res Bull. 2012;88(1):58-71. PMCID:PMC3263419  PMID:21855613 
  11. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol. 2011;13(1):28-41. PMCID:PMC3018903  PMID:21075781 
Last updated: 08/25/2021
© 2021 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130